Current Report Filing (8-k)
May 23 2019 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 22, 2019
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37348
|
|
46-4348039
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification
No.)
|
500 River Ridge Drive,
Norwood, MA
|
|
02062
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code:
(617) 963-0100
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
May 22, 2019, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual
Meeting”). The matters voted on at the Annual Meeting were: (1) the election of directors and (2) the ratification of the
appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal
year ending December 31, 2019. The final voting results were as follows:
1.
The election of each of Dr. Yuval Cohen, Alan Holmer, Avery W. Catlin, David P. Hochman, Rachelle Jacques, John Jenkins and Paris
Panayiotopoulos as directors to hold office for a term of one year, until his or her successor is duly elected and qualified or
he or she is otherwise unable to complete his or her term.
The
votes were cast for this matter as follows:
Nominees
|
|
Votes
For
|
|
Votes
Withheld
|
|
Broker
Non-Votes
|
Dr.
Yuval Cohen
|
|
11,488,156
|
|
2,336,550
|
|
36,452,982
|
Alan
Holmer
|
|
11,403,180
|
|
2,421,526
|
|
36,452,982
|
Avery
W. Catlin
|
|
11,462,575
|
|
2,362,131
|
|
36,452,982
|
David
P. Hochman
|
|
13,573,775
|
|
250,931
|
|
36,452,982
|
Rachelle
Jacques
|
|
13,564,305
|
|
260,401
|
|
36,452,982
|
John
Jenkins
|
|
13,598,107
|
|
226,599
|
|
36,452,982
|
Paris
Panayiotopoulos
|
|
9,972,414
|
|
3,852,292
|
|
36,452,982
|
2.
The proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm
for the Company’s fiscal year ending December 31, 2019 was approved based upon the following votes:
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
49,424,499
|
|
415,868
|
|
437,321
|
|
0
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORBUS PHARMACEUTICALS HOLDINGS,
INC.
|
|
|
|
Dated:
May 23, 2019
|
By:
|
/s/
Yuval Cohen
|
|
Name:
|
Yuval Cohen
|
|
Title:
|
Chief Executive Officer
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024